Validity of chronic drug exposure presumed from repeated patient interviews varied according to drug class

J Clin Epidemiol. 2012 Oct;65(10):1061-8. doi: 10.1016/j.jclinepi.2012.04.009. Epub 2012 Jul 21.

Abstract

Objective: To evaluate the validity of chronic drug exposure presumed from cross-sectional interviews taking reimbursement data as reference.

Study design and setting: The study concerned 2,985 elderly persons of the French Three-City cohort (1) who were interviewed on current drug use 2 and 4 years after inclusion and (2) whose reimbursement data were obtained from the main health care insurance system. Validity (sensitivity, Se; specificity, Sp; positive predictive value, PPV; negative predictive value, NPV) of chronic exposure presumed from follow-up interviews was investigated taking two exposure definitions from reimbursements as reference for the period between interviews: at least 80% coverage with and without a maximal time between reimbursements of 60 days.

Results: Using 80% coverage as reference, validity of interview data was substantial for cardiovascular and antithrombotic drugs (Se, 85.3-95.4%; Sp, 67.1-97.6%; PPV, 65.9-86.6%; NPV, 93.3-99.3%). For benzodiazepines, nonsteroidal anti-inflammatory drugs, or analgesics, validity was low especially owing to PPVs (15.8-51.4%).

Conclusion: Using reported use at cross-sectional interviews as a proxy for chronic exposure between interviews was valid for drugs used regularly but not so for drugs used more irregularly.

Publication types

  • Comparative Study
  • Multicenter Study
  • Validation Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cross-Sectional Studies
  • Drug Utilization / statistics & numerical data*
  • Female
  • France / epidemiology
  • Humans
  • Insurance, Health, Reimbursement / statistics & numerical data
  • Interviews as Topic*
  • Longitudinal Studies
  • Male
  • Pharmaceutical Preparations / classification
  • Pharmacoepidemiology / methods*
  • Pharmacoepidemiology / statistics & numerical data
  • Prevalence
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Pharmaceutical Preparations